Probiotics for a healthy biome. Including Saccharomyces Boulardii. And its role in neutralizing C Diff toxins. Search augmentation via OpenEvidence.com

https://www.openevidence.com/ask/e35d43f0-7ffc-4fd0-937b-dd0d11005a40

Excerpt from above:

Saccharomyces boulardii (S. boulardii) is a probiotic yeast with several key benefits for intestinal health, particularly in the context of Clostridioides difficile (C. difficile) infection (CDI).

Key Benefits:

1. Inhibition of Pathogens: S. boulardii produces proteases that inactivate C. difficile toxins A and B, reducing their pathogenicity.

2. Immune Modulation: It enhances the immune response by increasing the production of secretory IgA and modulating cytokine production.

3. Gut Barrier Function: S. boulardii helps maintain and restore the integrity of the intestinal barrier, reducing permeability and preventing translocation of pathogens.

Evidence for CDI Recurrence Prevention:

Several studies support the use of S. boulardii in preventing recurrent CDI:

• A multicenter double-blind RCT demonstrated a significant reduction in CDI recurrence when S. boulardii was used alongside metronidazole or vancomycin in patients with a history of recurrent CDI (RR 0.43, 34.6% with S. boulardii vs. 64.7% with placebo).

• A follow-up study showed benefits in a subgroup treated with high-dose vancomycin and S. boulardii, with a recurrence rate of 16.7% compared to 50% with placebo.

• A controlled prospective intervention study indicated that S. boulardii significantly reduced CDI rates in hospitalized patients receiving antibiotics (OR = 0.06, 95% CI 0.02-0.16).

Dosage:

The typical dosage used in clinical studies is 1 g/day, which corresponds to approximately 5 billion CFU, administered in divided doses.

Guideline Recommendations:

The American College of Gastroenterology (ACG) guidelines acknowledge the potential role of S. boulardii in preventing recurrent CDI, particularly in patients with a history of recurrence.

In summary, S. boulardii has demonstrated efficacy in reducing the recurrence of CDI, particularly when used in conjunction with standard antibiotic therapy in patients with a history of recurrent infections.

Feel free to share this post with friends and family. Thank you for taking the time to read this post